Company intelligence / Profile preview

RT MicroDx

Boston, Massachusetts, United Statesrtmicrodx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

RT MicroDx has developed a prototype at-home, readerless, saliva-based molecular diagnostic test using LAMP technology and proprietary hydrogel chemistry. Their lead product is an over-the-counter strep throat (Strep A) test with high reported accuracy (97% specificity, 99% sensitivity). Proof-of-concept studies are complete; the company is seeking capital to submit for FDA approval and begin first-in-human trials. No clinical trial data or regulatory approvals have been reported as of June 2025.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic test (specifically, Loop-mediated Isothermal Amplification - LAMP)Hydrogel-based diagnostic platform
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on RT MicroDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT MicroDx.

Explore the full profile